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Methods: Sixty ASA I children (4–10 years old) referred from the outpatient clinic of the pediatric
dentistry department for sedation for dental procedures. They were randomly classiﬁed into two
groups, group I (dexmedetomidine group) was given as 2 lg/kg loading dose over 5 min followed
by 0.4 lg/kg/h continuous infusion. Group II (midazolam–propofol group) midazolam was given
as 0.05 mg/kg and propofol was given loading dose as 1 mg/kg over 5 min followed by 5 mg/kg/h
continuous infusion. Heart rate, mean arterial blood pressure, oxygen saturation, respiratory rate
were recorded every 5 min till discharge. The onset of sedation, procedure time, recovery time, dis-
charge time and the need of analgesia were recorded. The incidence of occurrence of adverse effects
was observed.h El-shahed Mostafa Ryad,
018181.
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300 W.M.A. Al Taher et al.Results: In group I, the mean onset of sedation was signiﬁcantly longer than in group II, but recov-
ery time was signiﬁcantly shorter in group I than group II, there are signiﬁcantly hemodynamics
effects in the ﬁrst 15 min and more incidence of occurrence of side effects in group II than group
I. There are more analgesic effects of dexmedetomidine in group I than group II postoperatively.
Conclusion: Dexmedetomidine is safe and effective when used for sedation in pediatric patients
undergoing dental procedures.
ª 2010 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.Table 1 Ramsay sedation scale [9].
Score Response
1 Anxious or restless or both
2 Cooperative, oriented and tranquil (calm)
3 Responding to command
4 Brisk (quick) response to stimulus
5 Sluggish (slow moving) response to stimulus
6 No response to stimulus
Open access under CC BY-NC-ND license.1. Introduction
The ﬁeld of pediatric dentistry beholds the greatest challenge
among the various other branches of dentistry in providing
dental care without inﬂicting any adverse psychological impact
upon the child [1]. Uncooperative behavior in the dental set-
ting is most typically attributed to behavioral manifestations
of anxiety; such uncooperative behavior has been rated by den-
tists as being the major problem in the dental chair. Major
consequences of such uncooperative behavior may include a
delay or termination of treatment before completion, or a de-
crease in the quality of care provided [2]. Today modern pedi-
atric dentistry describes so many techniques to manage the
behavior of the child dental patient. The use of range of drugs
as adjuvant to behavioral psychology should enable the dentist
to handle most of unmanageable children [3]. Among drugs
used in conscious sedation, we can mention midazolam which
is a benzodiazepine derivative as well as propofol which is a
short acting intravenous sedative agent, but they are potential
respiratory depressant [4,5]. Dexmedetomidine is a centrally
acting a2 agonist that has sedative and analgesic effect and
shorter half-life of 1.5–3 h after intravenous dosing so make
it easier to titrate, quicker to recover [6]. Dexmedetomidine
provides sedation and analgesia with no accompanying respi-
ratory depression when administered within clinical dosing
guidelines even some consider that dexmedetomidine actually
mimics some aspects of natural sleep, however, it produces
dose dependant decrease in blood pressure and heart rate as
a result of its a2 agonist effect on the sympathetic ganglia with
resulting sympatholylic effects [7].
Propofol when used alone in uncooperative pediatric pa-
tients undergoing dental procedures was accompanied by pain
on injection and coughing despite rapid onset of action, while
midazolam when used showed the longest duration of action
but was not very effective in terms of treatment completion
due to increased movements and crying [8]. Thus combination
of small doses of midazolam with propofol can be considered
superior in sedation over single drug used. The aim of the
study is to compare the safety and efﬁcacy of midazolam–pro-
pofol combinations to dexmedetomidine for conscious seda-
tion in pediatric patients undergoing oro-dental procedures.
2. Methods
Following the approval from ethical committee and obtaining
parental written informed consent, 60 ASA I physical status
child aged 4–10 years old, were enrolled in the period between
December 2007 and December 2008 in general Anesthesia
Unit, Department of Pediatric and Preventive Dentistry, Fac-
ulty of Oral and Dental Medicine, Cairo University. Patients
enrolled have no history of drug allergy scheduled for dentalprocedure (pulpotomy with amalgam ﬁlling, cavity prepara-
tion with amalgam ﬁlling, teeth extraction) (Table 4), fasting
for 8 h with allowing clear ﬂuids up to 2 h; referred for seda-
tion. All children were subjected for complete medical exami-
nation, weighted in kg and sedative agent was prepared
according to the body weight. All patients had a 22G cannulae
inserted as an IV line before start of conscious sedation using
EMLA cream, then received 20 mg lidocaine 2% (1 ml) and
atropine 0.01 mg/kg as anti sialogouge, and O2 supplementa-
tion via a nasal cannulae at 4 l/min before the injection of
the sedative agent. All facilities for securing and maintaining
a patent airway, providing O2, artiﬁcial ventilation and cardio-
pulmonary resuscitation were available. Restraining belt was
applied to prevent unwanted movement during the procedure.
Children were then randomized into two equal groups using
closed envelope technique into group I (dexmedetomidine
group, n= 30) where 2 lg/kg dexmedetomidine was adminis-
tered over 5 min to achieve a Ramsay sedation scale (RSS) of
P5 (Table 1) [9], followed by of 0.4 lg/kg/h dexmedetomidine
as continuous infusion using a syringe pump, if at any time un-
wanted movement or unfavorable sedation level had been
achieved, the dentist is asked to stop the procedure momentar-
ily and increments of 0.4 lg/kg dexmedetomidine was adminis-
tered until the desired RSS P5 was restored. And group II
(propofol–midazolam group, n= 30) where 0.05 mg/kg
midazolam was administered followed by 1 mg/kg propofol
over 5 min to achieve a Ramsay sedation scale (RSS) of P5
(Table 1) [9] then continuous propofol infusion of 5 mg/kg/h
using a syringe pump, if at any time unwanted movement or
unfavorable sedation level had been achieved, the dentist is
asked to stop the procedure momentarily and increments of
0.5 mg/kg propofol was administered until the desired RSS
P5 was restored. Following randomization drugs were pre-
pared according to body weight and all syringes to be admin-
istered including loading, top up doses and maintenance were
covered by aluminum foil and code labeled. Syringes were gi-
ven to anesthetist that is blinded to experimental protocol.
Following sedation the dentist used local inﬁltration anesthesia
with lidocaine 2% at a maximum dose of 4 mg/kg.
Table 2 Steward Recovery score [10].
Consciousness
Awake 2
Responding to stimuli 1
Not responding 0
Airway
Coughing on command or crying 2
Maintaining good airway 1
Airway requires maintenance 0
Movement
Moving limbs purposefully 2
Non purposeful movements 1
Not moving 0
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A physician that is blinded to experimental protocol was given
a spread sheet titled by the label code of syringe and was asked
to complete the following data in the spread sheet.
Heart rate, mean arterial blood pressure, respiratory rate
and oxygen saturation were recorded prior to sedation and
then every 5 min till discharge, patients were discharged when
Steward Recovery score of 6 (Table 2) [10]. The following
times were also recorded:
 Onset of sedation = is the time from the end of the loading
dose to achievement of RSS of 5 or more.Table 3 The CHEOPS (Children’s Hospital of Eastern Ontario Pa
Item Behavioral Deﬁnition
Cry No cry 1 Child is not crying
Moaning 2 Child is moaning or quietly vo
Crying 2 Child is crying, but the cry is g
Scream 3 Child is in a full-lunged cry; so
Facial Composed 1 Neutral facial expression
Grimace 2 Score only if deﬁnite negative f
Smiling 0 Score only if deﬁnite positive f
Child verbal None 1 Child not talking
Other complaints 1 Child complains, but not abou
Pain complaints 2 Child complains about pain
Both Complaints 2 Child complains about pain an
Positive 0 Child makes any positive state
Torso Neutral 1 Body (not limbs) is at rest; tor
Shifting 2 Body is in motion in a shifting
Tense 2 Body is arched or rigid
Shivering 2 Body is shuddering or shaking
Upright 2 Child is in a vertical or uprigh
Restrained 2 Body is restrained
Touch Not touching 1 Child is not touching or grabb
Reach 2 Child is reaching for but not to
Touch 2 Child is gently touching wound
Grab 2 Child is grabbing vigorously at
Restrained 2 Child’s arms are restrained
Legs Neutral 1 Legs may be in any position bu
Squirm/kicking 2 Deﬁnitive uneasy or restless mo
Drawn up/tensed 2 Legs tensed and/or pulled up t
Standing 2 Standing, crouching or kneelin
Restrained 2 Child’s legs are being held dow Procedure time = is the time from achieving the required
RSS till the end of the procedure (stoppage of drug
infusion).
 Recovery time = is the time from stoppage of drug infusion
till reaching the RSS of 2.
 Discharge time = is the time from stoppage of drug infu-
sion till the discharge of the child from density clinic, Stew-
ard Recovery score of 6.
Incidence of occurrence of adverse effects, and unwanted
movements during the procedure were also recorded. Children
were then transferred to the recovery area where another phy-
sician blinded to the experimental protocol is responsible for
documenting the time at which child achieved Stewart Recov-
ery score of 6 and also he is responsible to observe the needs
for analgesia postoperatively according to CHEOPS (Chil-
dren’s Hospital of Eastern Ontario Pain Scale) [11] (Table 3);
analgesia will be declofenac 25 mg supp. when CHEOPS > 4.4. Statistical analysis
Parametric data are presented as mean ± SD. Nominal data
and qualitative data are presented as absolute value and %
of total. Hemodynamic data (HR, MAP, etc.) were analyzed
using repeated measure ANOVA; if statistical signiﬁcance
was reached a Tukey post hoc test was performed to identify
level of signiﬁcance. Age, weight and times recorded were ana-
lyzed using independent t-test, while gender, type of procedure,in Scale) [11].
calizing silent cry
entle or whimpering
bbing; may be scored with complaint or without complaint
acial expression
acial expression
t pain, e.g., ‘‘I want to see mommy’’ of ‘‘I am thirsty’’
d about other things, e.g., ‘‘It hurts; I want my mommy’’
ment or talks about others things without complaint
so is inactive
or serpentine fashion
involuntarily
t position
ing at wound
uching wound
or wound area
wound
t are relaxed; includes gentle swimming or separate-like movements
vements in the legs and/or striking out with foot or feet
ightly to body and kept there
g
n
Figure 2 Oxygen saturation (%). Group I = dexmedetomidine
group (n= 30) and group II = midazolam–propofol group
(n= 30).
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lyzed using chi-square or Fischer’s exact test as appropriate.
The software SPSS version 15.0 for windows was used for sta-
tistical analysis. A p-value < 0.05 was considered as statisti-
cally signiﬁcant.
5. Results
Sixty ASA physical status I children (4–10 years old) who were
referred for conscious sedation because of their anxiety and
behavior management problem from outpatient clinic of the
pediatric dentistry department, had completed the study proto-
col and dental procedure. Demographic data were comparable
among both groups (Table 4). Heart rate, oxygen saturation
and respiratory rates were comparable among both groups
and during all recorded times (Figs. 1–3).
Mean arterial blood pressure (MAP) was signiﬁcantly lower
in group II compared to group I at 5, 10 and 15 min
(p< 0.0001), also MAP in group II was signiﬁcantly lower
during same periods (5, 10 and 15 min) compared to baseline
and all other recorded times (Fig. 4).
Onset of sedation to achieve RSSP5 was extremely signif-
icantly longer in group I compared to group II (8.7 ± 1.8 ver-Table 4 Demographic data of the groups (mean ± SD).
Group I
(30 children)
Group II
(30 children)
p-value
Age (y) 6.7 ± 2.3 7.2 ± 2.2 0.39
Weight (kg) 23.4 ± 3.7 24.6 ± 3.6 0.21
Sex (M/F) (n) 16/14 18/12 0.79
Procedure performed
Pulpotomy with
amalgam ﬁlling
8 7 1.0
Cavity preparation with
amalgam ﬁlling
10 11 1.0
Teeth extraction 12 12 1.0
Figure 1 Mean heart rate in both groups. Group I = dexmede-
tomidine group (n= 30) and group II = midazolam–propofol
group (n= 30).
Figure 3 Respiratory rate (breath/min). Group I = dexmede-
tomidine group (n= 30) and group II = midazolam–propofol
group (n= 30).sus 4.4 ± 1.1 min, respectively, p< 0.0001). Also recovery
time to achieve a RSS of 2 was extremely signiﬁcantly shorter
in group I compared to group II (18.3 ± 5.9 versus
25.2 ± 8.2 min, respectively, p< 0.0004). However, the proce-
dure time which ranging from (14.4 ± 5.1) in group I versus
(14.2 ± 5.5) in group II and discharge times which ranging
from (19.2 ± 4.9) in group I versus (20.1 ± 3.9) in group II
were comparable among both groups (Table 5).
None of patients among both groups studied had experi-
enced any form of allergic reaction; none of patients had re-
quired mechanical ventilation. In group I 3 (10%) patients
had unwanted movements compared to 2 (6.7%) in group II,
p= 1.0. In group II 2 (6.7%) patients had experienced short
periods of apnea (>20 s and responded to bag and mask ven-
tilation) while none (0%) of patients had experienced any per-
iod of apnea in group I. Eight (26.7%) patients in group I
required supplemental analgesia in the recovery area compared
to 20 (66.7%) patients in group II, p= 0.004.
Figure 4 Mean arterial blood pressure (MAP mmHg). Group
I = dexmedetomidine group (n= 30) and group II = midazo-
lam–propofol group (n= 30). * Denotes signiﬁcantly lower com-
pared to other measurements within the same group (p< 0.0001).
 Denotes signiﬁcantly lower compared to group I (dexmedetom-
idine) (p< 0.0001).
Table 5 Onset time of sedation, procedure time, recovery
time, and discharge time represented in form of mean ± stan-
dard deviation.
Measurement Group I
(n= 30)
Group II
(n= 30)
p-value
Onset time of sedation (min) 8.7 ± 1.8* 4.4 ± 1.1 >0.0001
Procedure time (min) 14.4 ± 5.1 14.2 ± 5.5 0.88
Recovery time (min) 18.3 ± 5.9* 25.2 ± 8.2 0.0004
Discharge time (min) 19.2 ± 4.9 20.1 ± 3.9 0.43
* Denotes signiﬁcance.
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The main ﬁnding in the current randomized trial involving 60
ASA I physical status children (4–10 years) requiring sedation
during dentistry procedure at a dentistry outpatient clinic can
be summarized as follows: (A) Both sedative techniques (dex-
medetomidine versus propofol–midazolam) can be used safely
in outpatient dentistry clinic. (B) Propofol–midazolam combi-
nation can achieve rapid induction compared to dexmedetom-
idine alone, reﬂected by shorter duration required to achieve
RSSP5. (C) Dexmedetomidine had faster recovery compared
to propofol–midazolam combinations reﬂected by rapid resto-
ration of RSS of 2. (D) Patients receiving dexmedetomidine re-
quires less analgesia supplementation in the early recovery
period compared to propofol–midazolam combination.
Adequate anxiety control is a fundamental part of the prac-
tice of dentistry, conscious sedation is a technique in which the
use of a drug or drugs produces a state of depression of the
central nervous system enabling treatment to be carried out,
but during which verbal contact with the patient is maintained
throughout the period of sedation, it is important that a wide
margin of safety for conscious sedation is maintained [12].
Oxygen supplementation is considered to be an important is-sue in conscious sedation to minimize desaturation even in
presence of apnea [12]. In the current study no signiﬁcant ad-
verse effects had been associated with both sedative tech-
niques, also efﬁcacy of both sedative technique were
comparable reﬂected by comparable number of patients that
showed undesired movements during the procedure 3 in group
I compared to 2 in group II. The main difference in regard to
safety was that patients in group II had demonstrated transient
reversible decrease in their mean arterial blood pressure
(Fig. 4) and that 2 patients had experienced short period of ap-
nea that responded to bag and mask ventilation in group II
while all patients in group I demonstrated intact respiratory
drive and comparable hemodynamic parameters throughout
the whole procedure. Dexmedetomidine exerts its effects by
binding to a2 receptors presynaptically and postsynaptically
in the locus ceruleus and in the spinal cord. It decrease norepi-
nephrine release and inhibits sympathetic activity. The inhibi-
tion of sympathetic activity may lower heart rate and blood
pressure [13]. In the current trial dexmedetomidine exhibits a
very stable hemodynamics and the mainstay is that in both
groups atropine sulphate were administered and we believe
that such premedication was responsible for abolishing brady-
cardia associated with dexmedetomidine with subsequent
hypotension. Moreover in a comparative study between effects
of dexmedetomidine and propofol, in adult population, the
dexmedetomidine treated patients showed higher blood pres-
sures compared to propofol group with an average of
11 ± 3 mmHg [14] and that ﬁnding is consistent with our ﬁnd-
ing at times where blood pressure had dropped (5, 10 and
15 min). However, we can tell that in regard to safety and
efﬁcacy.
In the current study we demonstrated rapid onset of seda-
tion with midazolam–propofol combinations compared to
dexmedetomidine alone (4.4 ± 1.1 min versus 8.7 ± 1.8 min).
Arian and Ebert [14] demonstrated rapid onset of targeted
sedation level with propofol (10 min) compared to dexmede-
tomidine (25 min). Although we demonstrated rapid onset of
sedation with propofol over dexmedetomidine, however, our
onset of targeted sedation in both groups were faster than
those reported by Arian. First, in Arian study he used bispec-
tral index (BIS) targeted to 70–80, second he used propofol in
doses of 75 lg/kg as loading dose unlike us we used 1 mg/kg as
loading dose together with 0.05 mg/kg midazolam, Third, the
loading dose for dexmedetomidine in his trial was 1 lg/kg over
10 min while we used 2 lg/kg over 5 min, ﬁnally patient popu-
lation is different in both trials as we were dealing with pediat-
ric population 4–10 years while in his trial average patient
population was 62 years.
Reports for recovery times in respect to dexmedetomidine
use had been reported with great variability; in the current trial
it was signiﬁcantly shorter in dexmedetomidine group than the
combination group. In agreement with our ﬁnding Venn and
Grounds [15] and Lee et al. [16] had reported faster recovery
times when dexmedetomidine was used, however, Koroglu et
al. [17] reported that there is no difference regarding the recov-
ery time between the dexmedetomidine and propofol.Moreover
Pandharipande et al. [18] demonstrated longer recovery times
with dexmedetomidine compared to lorazepam. These conﬂict-
ing results regarding recovery times can be attributed to one of
the most interesting properties of dexmedetomidine, which is
the ability to achieve sedation with preserved arousability
[6,19], thus rendering judging on recovery time to be more
304 W.M.A. Al Taher et al.subjective rather than objective. And in most reports even if
recovery time was prolonged such times did not affect discharge
criteria [14–18]. In the current trial we experienced better recov-
ery time with dexmedetomidine compared to combination
group (18.3 ± 5.9 versus 25.2 ± 8.2 min) while discharge times
were comparable among both groups (Table 5). In this respect
we can attribute prolonged recovery times in combination
group to the use of midazolam with propofol and in this respect
we had previous reports regarding thatmidazolamwhen used in
pediatric dentistry demonstrated longer duration of action com-
pared to propofol and ketamine [8].
Also in the current trial patients receiving dexmedetomidine
required less analgesic supplementation compared to the com-
bination group, in fact this ﬁnding is consistent with numerous
reports due to analgesic effect of the a2 agonist dexmedetomi-
dine. Arian and Ebert [14] demonstrated that patients who re-
ceived dexmedetomidine for sedation had reduced pain scores
and reduced use of morphine compared to propofol patients,
also in a subsequent paper. Arian et al. [20] demonstrated that
dexmedetomidine was superior than patients receiving mor-
phine alone for postoperative analgesia. The analgesic effects
of dexmedetomidine had also been appreciated in various set-
tings and various patient populations [21–26].
In summary, we can tell that both sedative techniques were
safe and effective and can be used to alleviate anxiety,
unwanted movements and provide adequate sedation for pedi-
atrics undergoing dental procedures. The fact that dexmede-
tomidine had possessed relatively more stable hemodynamic
and respiratory proﬁles, together with adequate postoperative
analgesia renders such drug to be in a superior position. How-
ever, such statement should be thoroughly investigated, since
dexmedetomidine was only FDA approved as a sedative for
non intubated patients only on late 2008, thus it is difﬁcult to
ﬁnd randomized controlled trials that focuses in such issue.
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